MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Collaborator to Start Pivotal Study with Bimagrumab
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys to Receive Clinical Milestone Payment
MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced
today that its collaborator Novartis has initiated a phase 2/3 clinical trial in
sporadic inclusion body myositis (sIBM) patients with the HuCAL-derived antibody
bimagrumab (BYM338). The event triggered a clinical milestone payment to
MorphoSys. Further financial details were not disclosed.
Bimagrumab (BYM338) is a novel, fully human monoclonal antibody developed to
treat pathological muscle loss and weakness. Bimagrumab was developed by the
Novartis Institutes for Biomedical Research (NIBR), in collaboration with
MorphoSys, whose HuCAL library was used to identify the antibody. Bimagrumab
binds with high affinity to type II activin receptors, preventing natural
ligands from binding, including myostatin and activin. Bimagrumab stimulates
muscle growth by blocking signaling from these inhibitory molecules. Novartis
received FDA breakthrough therapy designation for bimagrumab for sporadic
inclusion body myositis in August 2013. In addition to being developed in sIBM,
bimagrumab is in clinical development for chronic obstructive pulmonary disease
(COPD), cancer cachexia, sarcopenia and in mechanically ventilated patients.
"Our pipeline of both partner and proprietary antibody drugs represents the main
value driver for MorphoSys and we are therefore delighted to see one of the most
exciting and innovative HuCAL-based antibody programs advance into the next
stage of clinical development. Bimagrumab is the second HuCAL antibody to enter
pivotal studies," commented Dr. Marlies Sproll, Chief Scientific Officer of
MorphoSys AG.
MorphoSys's clinical pipeline now comprises 21 programs. Of these, 17 are
programs that were initiated by partners, of which two are in Phase 3
development eight are in Phase 2 and seven are in Phase 1. From the company's
proprietary portfolio, MOR202, which is being co-developed with Celgene, is in a
phase 1/2a trial for multiple myeloma. MOR208 is currently being evaluated in
two phase 2 trials in B-ALL and NHL. MOR103, partnered with GSK, has concluded a
phase 1b/2a trial in rheumatoid arthritis, and is currently being evaluated in a
phase 1b trial in multiple sclerosis.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
MorphoSys AG.
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Mario Brkulj
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Alexandra Goller
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1732410/579920.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE
[HUG#1732410]
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2013 - 07:31 Uhr
Sprache: Deutsch
News-ID 301991
Anzahl Zeichen: 5726
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Collaborator to Start Pivotal Study with Bimagrumab"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
